Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010

Seiji Naito, Yoshiyuki Kakehi, Akihiko Okuyama, Tomoaki Imamura, Hideo Yasunaga, Hideyuki Akaza, Shiro Hinotsu, Yoichi Arai, Takushi Dokiya, Shin Egawa, Kazuhiro Suzuki, Hirofumi Koga, Naoya Masumori, Koichiro Akakura, Kiyotaka Kawashima, Koji Okihara, Kazuto Ito

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8-fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.

Original languageEnglish
Pages (from-to)830-838
Number of pages9
JournalInternational Journal of Urology
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 2010
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Guidelines
Japan
Mortality

Keywords

  • guidelines
  • prostate cancer
  • PSA
  • screening

ASJC Scopus subject areas

  • Urology

Cite this

Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. / Naito, Seiji; Kakehi, Yoshiyuki; Okuyama, Akihiko; Imamura, Tomoaki; Yasunaga, Hideo; Akaza, Hideyuki; Hinotsu, Shiro; Arai, Yoichi; Dokiya, Takushi; Egawa, Shin; Suzuki, Kazuhiro; Koga, Hirofumi; Masumori, Naoya; Akakura, Koichiro; Kawashima, Kiyotaka; Okihara, Koji; Ito, Kazuto.

In: International Journal of Urology, Vol. 17, No. 10, 10.2010, p. 830-838.

Research output: Contribution to journalArticle

Naito, S, Kakehi, Y, Okuyama, A, Imamura, T, Yasunaga, H, Akaza, H, Hinotsu, S, Arai, Y, Dokiya, T, Egawa, S, Suzuki, K, Koga, H, Masumori, N, Akakura, K, Kawashima, K, Okihara, K & Ito, K 2010, 'Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010', International Journal of Urology, vol. 17, no. 10, pp. 830-838. https://doi.org/10.1111/j.1442-2042.2010.02613.x
Naito, Seiji ; Kakehi, Yoshiyuki ; Okuyama, Akihiko ; Imamura, Tomoaki ; Yasunaga, Hideo ; Akaza, Hideyuki ; Hinotsu, Shiro ; Arai, Yoichi ; Dokiya, Takushi ; Egawa, Shin ; Suzuki, Kazuhiro ; Koga, Hirofumi ; Masumori, Naoya ; Akakura, Koichiro ; Kawashima, Kiyotaka ; Okihara, Koji ; Ito, Kazuto. / Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. In: International Journal of Urology. 2010 ; Vol. 17, No. 10. pp. 830-838.
@article{53ce5130c7e64a3dbd20a7f2801e032e,
title = "Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010",
abstract = "The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8-fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.",
keywords = "guidelines, prostate cancer, PSA, screening",
author = "Seiji Naito and Yoshiyuki Kakehi and Akihiko Okuyama and Tomoaki Imamura and Hideo Yasunaga and Hideyuki Akaza and Shiro Hinotsu and Yoichi Arai and Takushi Dokiya and Shin Egawa and Kazuhiro Suzuki and Hirofumi Koga and Naoya Masumori and Koichiro Akakura and Kiyotaka Kawashima and Koji Okihara and Kazuto Ito",
year = "2010",
month = "10",
doi = "10.1111/j.1442-2042.2010.02613.x",
language = "English",
volume = "17",
pages = "830--838",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010

AU - Naito, Seiji

AU - Kakehi, Yoshiyuki

AU - Okuyama, Akihiko

AU - Imamura, Tomoaki

AU - Yasunaga, Hideo

AU - Akaza, Hideyuki

AU - Hinotsu, Shiro

AU - Arai, Yoichi

AU - Dokiya, Takushi

AU - Egawa, Shin

AU - Suzuki, Kazuhiro

AU - Koga, Hirofumi

AU - Masumori, Naoya

AU - Akakura, Koichiro

AU - Kawashima, Kiyotaka

AU - Okihara, Koji

AU - Ito, Kazuto

PY - 2010/10

Y1 - 2010/10

N2 - The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8-fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.

AB - The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8-fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.

KW - guidelines

KW - prostate cancer

KW - PSA

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=77957285276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957285276&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2010.02613.x

DO - 10.1111/j.1442-2042.2010.02613.x

M3 - Article

VL - 17

SP - 830

EP - 838

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 10

ER -